Lien Thuy Tran

Array ( [id] => 18770833 [patent_doc_number] => 20230365633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => GRIFFITHSIN FOR RHABDOVIRIDAE INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/030174 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612195 [patent_doc_number] => 20210030848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ELEVATED INTRACRANIAL PRESSURE TREATMENT [patent_app_type] => utility [patent_app_number] => 17/065753 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075901 [patent_doc_number] => 20220401513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => ANTIVIRAL PEPTOID COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/640322 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18329237 [patent_doc_number] => 11634465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Analogues of VDAC1-derived peptides [patent_app_type] => utility [patent_app_number] => 17/039042 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 46 [patent_no_of_words] => 13413 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17946074 [patent_doc_number] => 20220333091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => RECOMBINANT BOTULINUM NEUROTOXIN WITH IMPROVED SAFETY MARGIN AND REDUCED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 17/765016 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581498 [patent_doc_number] => 20210015900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => GLA DOMAINS AS THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/032162 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18167598 [patent_doc_number] => 20230034205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => PEPTIDE, AND CELL FUSION AGENT AND PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY CONTAINING SAID PEPTIDE [patent_app_type] => utility [patent_app_number] => 17/753919 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612230 [patent_doc_number] => 20210030883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER [patent_app_type] => utility [patent_app_number] => 17/020613 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17020613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844914 [patent_doc_number] => 11434267 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Peptides having reduced toxicity that stimulate cholesterol efflux [patent_app_type] => utility [patent_app_number] => 17/016541 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 37822 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958679 [patent_doc_number] => 20220339259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/640817 [patent_app_country] => US [patent_app_date] => 2020-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496508 [patent_doc_number] => 11285192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Formulation including a combination of beta-endorphin and adrenocorticotropic hormone [patent_app_type] => utility [patent_app_number] => 17/008202 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10979 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17944388 [patent_doc_number] => 20220331405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => APTAMER ASSEMBLIES FOR PROTEIN CROSSLINKING [patent_app_type] => utility [patent_app_number] => 17/636715 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17392499 [patent_doc_number] => 11241487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders [patent_app_type] => utility [patent_app_number] => 17/001667 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 105 [patent_no_of_words] => 22529 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929786 [patent_doc_number] => 20220324911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => THERAPEUTIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/634433 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20157007 [patent_doc_number] => 12383605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Exenatide analog and use thereof [patent_app_type] => utility [patent_app_number] => 17/635039 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 10229 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232039 [patent_doc_number] => 20240189230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/634975 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627510 [patent_doc_number] => 20210046163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => THERAPEUTIC SYSTEMS, DEVICES, AND COMPOSITIONS WITH WOUND HEALING AND TISSUE REGENERATIVE PROPERTIES, USES THEREOF, AND CORRESPONDING METHODS [patent_app_type] => utility [patent_app_number] => 16/989808 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452591 [patent_doc_number] => 20200362017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => MIMETIC PEPTIDES DERIVED FROM COLLAGEN TYPE IV AND THEIR USE FOR TREATING ANGIOGENESIS- AND LYMPHANGIOGENESIS- DEPENDENT DISEASES [patent_app_type] => utility [patent_app_number] => 16/989411 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19884207 [patent_doc_number] => 12269900 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Inhibitors of b integrin-G protein a subunit binding interactions [patent_app_type] => utility [patent_app_number] => 16/988287 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 98 [patent_no_of_words] => 43078 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369946 [patent_doc_number] => 20220024998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => IMMUNOMODULATING PEPTIDE DERIVED FROM CONCAVE-EARED TORRENT FROG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/299472 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299472 [rel_patent_id] =>[rel_patent_doc_number] =>)